三生制药(01530.HK) 公布,与全资附属沈阳三生及辉瑞(PFE.US) 于昨日(19日)订立独家许可协议,将向辉瑞授予独家许可,以在中国内地以外的全球地区开发、生产、商业化及以其他方式开发其突破性PD-1/VEGF双特异性抗体(SSGJ-707)。三生制药及沈阳三生将保留许可产品于中国内地的开发、制造、商业化及其他开发权,辉瑞则拥有在中国商业化许可产品的选择权。许可首付款为12.5亿美元,...
Source Link三生制药(01530.HK) 公布,与全资附属沈阳三生及辉瑞(PFE.US) 于昨日(19日)订立独家许可协议,将向辉瑞授予独家许可,以在中国内地以外的全球地区开发、生产、商业化及以其他方式开发其突破性PD-1/VEGF双特异性抗体(SSGJ-707)。三生制药及沈阳三生将保留许可产品于中国内地的开发、制造、商业化及其他开发权,辉瑞则拥有在中国商业化许可产品的选择权。许可首付款为12.5亿美元,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.